Treatment of older breast cancer patients with high recurrence risk

Critical Reviews in Oncology/Hematology

Volumn 46, Issue 3, 2003, Pages 241-246

  Crivellari, D ^a   Spazzapan, S ^a   Lombardi, D ^a   Berretta, M ^a   Magri, M D ^a   Sorio, R ^a   Scalone, S ^a   Veronesi, A ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Adjuvant therapy; High risk elderly breast cancer patients

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LETROZOLE; PREDNISOLONE; PROGESTERONE RECEPTOR; TAMOXIFEN; VINCRISTINE;

AGE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CYSTITIS; DEHYDRATION; DIARRHEA; FEMALE; FUNCTIONAL ASSESSMENT; GASTRITIS; GERIATRIC DISORDER; HEALTH STATUS; HIGH RISK PATIENT; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; LIFE EXPECTANCY; LYMPH NODE METASTASIS; MEDICAL ASSESSMENT; MUCOSA INFLAMMATION; PLOIDY; POPULATION RESEARCH; PROGNOSIS; RECURRENCE RISK; SENESCENCE; SURVIVAL TIME; THROMBOEMBOLISM; TUMOR VOLUME; VASCULAR DISEASE;

EID: 0038182197     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00023-4     Document Type: Conference Paper

References (19)

1. Satariano W.A., Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann. Intern. Med. 120:1994;104-110.
2. Diab S.G., Elledge R.M., Clark G.M. Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl. Cancer Inst. 92:2000;550-556.
3. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 352:1998;930-942.
4. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.
5. Baum M. The ATAC (Arimidex, Tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal women. Breast Cancer Res Treat 2001;69(3), abstract 8.
6. Clark G.M. Prognostic and predictive factors. Harris J.R., Lippman M.E., Morrow M., et al. Diseases of the breast. 2nd ed:2000;489-514 Lippincott Williams and Wilkins, Philadelphia.
7. Extermann M., Balducci L., Lyman G.H. What threshold for adjuvant therapy in older breast cancer patients? J. Clin. Oncol. 18:2000;1709-1717.
8. Repetto L., Fratino L., Audisio R.A., et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group Performance Status in elderly cancer patients: AAAn Italian group for geriatric oncology study. J. Clin. Oncol. 20:2002;494-502.
9. Katz S., Ford A.B., Moskowitz R.W., et al. Studies of illness in the aged. The index of ADL-A standardized measure of biological and psychosocial function. J. Am. Med. Assoc. 185:1963;94-99.
10. Lawton M.P. Scales to measure competence in everyday activities. Psychopharmacol. Bull. 24:1988;609-614.
11. Rivkin S.E., Green S., Metch B., et al. Adjuvant CMFVP vs tamoxifen vs concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients. A Southwest Oncology Group Study. J. Clin. Oncol. 12:1994;2078-2085.
12. Pritchard K.I., Paterson A.H., Fine S., et al. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J. Clin. Oncol. 15:1997;2302-2311.
13. Anonymous. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. International Breast Cancer Study Group. J. Clin. Oncol. 15:1997;1385-1394.
14. Crivellari D., Bonetti M., Castiglione-Gertsch M., et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J. Clin. Oncol. 18:2000;1412-1422.
15. Fisher B., Redmond C., Legault-Poisson S., et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J. Clin. Oncol. 8:1990;1005-1018.
16. Ibrahim N.K., Buzdar A.U., Asmar L., et al. Doxorubicin based adjuvant chemotherapy in elderly breast cancer patients: The M.D. Anderson experience, with long-term follow-up. Ann. Oncol. 1:2000;1597-1601.
17. Wils J.A., Bliss J.M., Marty M., et al. Epirubicin plus tamoxifen vs tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J. Clin. Oncol. 17:1999;1988-1998.
18. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J. Clin. Oncol. 19:2001;3817-3827.
19. Strawbridge W.J., Shema S.J., Balfour J.L., et al. Antecedents of frailty over three decades in an older cohort. J. Gerontol. 53:1998;S9-S16.